[Adjuvant hormone therapy in endometrial carcinoma: medroxyprogesterone acetate versus tamoxifen-medroxyprogesterone acetate sequential therapy].
A prospective randomized study of 195 patients with endometrial cancer, who were treated by adjuvant hormone therapy, is reported. 100 patients received 100 mg medroxyprogesterone acetate alone, 95 a combination of medroxyprogesterone acetate and tamoxifen (2 x 10 mg). Our data show no statistical difference between the two groups.